499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipatasertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Larotrectinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Ociperlimab Hepatocellular Carcinoma	BeiGene	P2	CCC (52)
Olanzapine Hepatocellular Carcinoma	OHSU Knight Cancer Institute	P2	CCC (52)
Pertuzumab Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Pevonedistat Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Pracytarabine Hepatocellular Carcinoma	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	P2/3	CCC (52)
rbs2418 Hepatocellular Carcinoma	Riboscience, LLC.	P2	CCC (52)
SIN-1A Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	CCC (52)
Tenofovir Hepatocellular Carcinoma	Zhongshan Hospital (Xiamen), Fudan University	P3	CCC (52)
Trastuzumab Emtansine Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Vismodegib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Visugromab Hepatocellular Carcinoma	CatalYm GmbH	P2	CCC (52)
vrt106 Hepatocellular Carcinoma	Guangzhou Virotech Pharmaceutical Co., Ltd.	P2/3	CCC (52)
Allostim® Hepatocellular Carcinoma	Mirror Biologics, Inc.	P2/3	CCC (51)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Hepatocellular Carcinoma	Fudan University	P2	CCC (51)
Indometacinum Hepatocellular Carcinoma	National Taiwan University Hospital	P2	CCC (51)
Kras Tcr-Transduced Pbl Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Shr-1826 Hepatocellular Carcinoma	Shanghai Zhongshan Hospital	P2	CCC (51)
Sitravatinib Hepatocellular Carcinoma	BeiGene	P3	CCC (51)
Taselisib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Taurursodiol Hepatocellular Carcinoma	Fudan University	P2	CCC (51)
ACETIC Hepatocellular Carcinoma	M.D. Anderson Cancer Center	P2	CCC (50)
Aspirin Hepatocellular Carcinoma	Yonsei University	P3	CCC (50)
Becavizumab Hepatocellular Carcinoma	Hoffmann-La Roche	P3	CCC (50)
Fianlimab Hepatocellular Carcinoma	Virginia Commonwealth University	P2	CCC (50)
Granisetron Hepatocellular Carcinoma	Guangxi Medical University	P3	CCC (50)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Hepatocellular Carcinoma	Virginia Commonwealth University	P2	CCC (50)
Liocyx-M Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P2	CCC (50)
Neoantigen Dendritic Cell Vaccine Hepatocellular Carcinoma	National Cancer Centre, Singapore	P2	CCC (50)
Nivestim Hepatocellular Carcinoma	Mayo Clinic	P2	CCC (50)
Nofazinlimab Hepatocellular Carcinoma	CStone Pharmaceuticals	P3	CCC (50)
NWRD06 Hepatocellular Carcinoma	Newish Technology (Beijing) Co., Ltd.	P2	CCC (50)
Obinutuzumab Hepatocellular Carcinoma	Simcha IL-18, Inc.	P1/2	CCC (50)
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Hepatocellular Carcinoma	Guangxi Medical University	P3	CCC (50)
Piflufolastat Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (50)
scg101 Hepatocellular Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (50)
sh006 Hepatocellular Carcinoma	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P2/3	CCC (50)
Trastuzumab Hepatocellular Carcinoma	Fate Therapeutics	P2	CCC (50)
Zinc Acexamate Hepatocellular Carcinoma	Hospital Universitari Vall d'Hebron Research Institute	P3	CCC (50)
Absk-011 Hepatocellular Carcinoma	Abbisko Therapeutics Co, Ltd	P2	CCC (49)
Amino Acids, Branched-Chain Hepatocellular Carcinoma	Fudan University	P2	CCC (49)
Amivantamab-Vmjw Hepatocellular Carcinoma	Janssen Research & Development, LLC	P2	CCC (49)
Avelumab Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	CCC (49)
Epalrestat Hepatocellular Carcinoma	Haibo Shao	P2	CCC (49)
Eparlitozoviril Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (49)
Geptanolimab Hepatocellular Carcinoma	Stephen Chan Lam	P2	CCC (49)
Hdac Inhibitor Cxd101 Hepatocellular Carcinoma	Stephen Chan Lam	P2	CCC (49)
hlx43 Hepatocellular Carcinoma	Shanghai Henlius Biotech	P2	CCC (49)
hlx53 Hepatocellular Carcinoma	Shanghai Henlius Biotech	P2	CCC (49)

Showing 151 to 200 of 499 assets

PreviousPage 4 of 10Next